OncoMatch/Clinical Trials/NCT07014410
Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer
Is NCT07014410 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies pyrotinib dalpiciclib letrozole for breast cancer.
Treatment: pyrotinib dalpiciclib letrozole — This is a a multicenter Phase II clinical study investigating efficacy of pyrotinib combined with dalpiciclib combined with letrozole in ER-positive and HER2-positive advanced breast cancer patients. The sample size is 63.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Endocrine / hormonal
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 positive expression
positive ER expression
Required: HER2 (ERBB2) positive expression
positive HER2 expression
Disease stage
Metastatic disease required
Demographics
Prior therapy
Cannot have received: cdk4/6 inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07014410 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cdk4/6 inhibitor disqualifies patients from enrollment.
Does this trial require ESR1?
Yes, ESR1 positive expression is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 positive expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify